The company is focusing on two main tracks: Cellular Longevity, which is describes as mechanistic, biomarker-driven solutions addressing cellular health and the biology of aging; and Experiential Longevity, which translates those cellular mechanisms of aging into benefits consumers can feel in daily life.
The initiative marks a “big shift for PLT”, said Steve Fink, the company’s VP of marketing, during an interview at the recent Vitafoods Europe event in Barcelona.
“Younger consumers are already buying longevity-relevant products and are looking for next-generation solutions that will address mechanisms of longevity before they lead to decline,” he said. “This group is in the best position to build lifelong supplement habits that the pursuit of longevity will require and capturing them will result in 30 years of loyalty. Our dual-track approach in the PLT Longevity Initiative is designed to help brands meet those consumers where they are and give them the innovation and scientific support they are looking for.”
Balancing short-term benefits with longer-term health
The approach is in-line with recommendations from the Future of Wellness research by McKinsey & Company, published last year.
According to the consultancy’s survey data, up to 60% of consumers across markets cited healthy aging as a “top” or “very important” priority.
“There has been a cultural shift among younger generations to take a proactive approach to healthy aging rather than a reactive one,” stated the report. “Longevity-focused products and services will continue to appeal to these younger consumers, but retaining these consumers is not without its challenges. Players should emphasize the short-term benefits of their products, in addition to the longer-term merits: A product that claims to improve mitochondrial function in the long term, for instance, could also highlight its immediate benefits, such as higher energy levels or reduced fatigue.”
Devin Stagg, president of PLT Health Solutions, noted that the company’s view is that longevity has to stay grounded in mechanistic science, but it also has to connect with tangible and meaningful outcomes that consumers can actually feel.
“Many current longevity solutions are future-focused investments that require a degree of belief in long term outcomes,” he said. “Experiential Longevity lets consumers feel the benefits of impacting these key mechanisms in the near term while the foundational work continues to pay dividends over a lifetime.”
Kinexa
The first major proof point for PLT’s new strategic approach comes in the form of data from a six-month randomized clinical study on the Kinexa Joint Longevity Complex, a patented combination of standardized extracts of Haritaki (Terminalia chebula), Turmeric (Curcuma longa), and Indian Frankincense (Boswellia serrata).
PLT’s head of innovation and clinical science, Jennifer Murphy, told NutraIngredients the company took a systems approach and looked at the joint as not just a sliver of cartilage, but everything that goes into supporting a healthy joint: the cartilage, meniscus, ligaments, synovium, and subchondral bone.
While the study included people with osteoarthritis, the data can be related to healthy aging because age-related declines in the joint make it more susceptible to osteoarthritis. “How can we delay that transition to osteoarthritis? How can we keep the joint healthy?” she said.
And that thinking makes Kinexa appropriate for people in their thirties and to groups like former high-level athletes, she said.
The study included 100 people aged between 40 and 75 with Grade II or III osteoarthritis. Participants were randomly assigned to receive either 200 mg/day of Kinexa or placebo for six months. The researchers measured a range of outcomes, including WOMAC, VAS, and Lequesne Functional Index (LFI) scores. Functional measures included isometric knee torque, a 6-minute walk test, and a Timed Get Up and Go test. The study also incorporated advanced MRI imaging techniques.
The data indicated that Kinexa was associated with a 24% improvement in knee strength, a 10% improvement in cartilage thickness, a 4.2% improvement in cartilage composition, a 26% improvement in joint functional capacity, a 60% improvement in joint comfort, and 49% reduction in joint stiffness.
The results were presented in Barcelona by Jeremy Appleton, ND, PLT’s director of medical and scientific affairs and have also been accepted for Nutrition 2026, the annual conference of the American Nutrition Society.
“Kinexa shows how impacting cellular mechanisms can translate into benefits that matter in daily life. That is the essence of Experiential Longevity,” said Murphy.
